NEW YORK, August 8, 2026, 17:09 EDT — U.S. markets have finished trading for the day.
- Johnson & Johnson finished Friday at $259.24, rising 0.9% for the session and up 1.1% for the week.
- Deal expenses lowered the midpoint of adjusted earnings forecast for 2026 by 5.5%, while revenue guidance was left unchanged.
- FactSet’s mean price target stands at $277.81, representing a 7.2% potential gain. The consensus rating continues to be Overweight.
Johnson & Johnson closed Friday at $259.24, marking its highest finish since July 29. Shares remain 5.7% under the 52-week high of $274.90.
The key indicator was valuation. J&J has rebounded even though its short-term profit forecast has been significantly lowered.
The buyout of Firefly Bio together with the collaboration with Sail Biomedicines lowered the 2026 adjusted profit midpoint by $0.64, representing a 5.5% decrease compared to the previous outlook.
| 2026 outlook measure | Before Firefly and Sail | Current | Change |
|---|---|---|---|
| Adjusted EPS range | $11.60–$11.75 | $10.96–$11.11 | Reduced |
| Adjusted EPS midpoint | $11.675 | $11.035 | -$0.640 |
| Price/midpoint at $259.24 | 22.2 times | 23.5 times | +1.3 turns |
| Reported sales range | $100.8B–$101.4B | $100.8B–$101.4B | No change |
Based on Friday’s close, J&J is valued at 23.5 times the updated midpoint. That price reflects 22.2 times the previous midpoint. These figures indicate that investors appear to be viewing much of the dilution as an investment in the pipeline, not as a sign of declining operations.
The stock’s week was mixed. It declined following Monday’s open but rebounded over the last three sessions.
| Session | Closing price | Daily change |
|---|---|---|
| Monday, August 3 | $254.41 | -0.76% |
| Tuesday, August 4 | $254.93 | +0.20% |
| Wednesday, August 5 | $257.59 | +1.04% |
| Thursday, August 6 | $256.98 | -0.24% |
| Friday, August 7 | $259.24 | +0.88% |
Major healthcare peers showed varied performance on Friday. Pfizer advanced, while Abbott and Eli Lilly fell.
| Company | Friday close | Friday move | Approximate market value |
|---|---|---|---|
| Johnson & Johnson NYSE:JNJ | $259.24 | up 0.89% | $633B |
| Pfizer Inc. NYSE:PFE | $26.76 | rallied 2.10% | $153B |
| Merck & Co. NYSE:MRK | $128.58 | rose 0.16% | $317B |
| Abbott Laboratories NYSE:ABT | $107.81 | slipped 0.15% | $188B |
| Eli Lilly and Co. NYSE:LLY | $1,185.71 | fell 0.58% | $1.06T |
Analyst sentiment has improved, with FactSet reporting 19 Buy or Overweight ratings, up from 17 three months ago.
| Analyst rating | Three months prior | One month prior | Latest |
|---|---|---|---|
| Buy | 12 | 13 | 14 |
| Overweight | 5 | 5 | 5 |
| Hold | 10 | 7 | 6 |
| Underweight | 2 | 0 | 0 |
| Sell | 0 | 1 | 1 |
| Consensus | Overweight | Overweight | Overweight |
The target spread shows a more cautious outlook compared to the ratings mix. According to FactSet, the average target of $277.81 suggests a potential upside of 7.2%. The median target of $280 points to an 8.0% gain. The lowest target, at $210, indicates a possible downside of 19%.
The foundation of operations continues to be strong. Sales for the second quarter climbed 6.6% to $25.31 billion. Revenue from Innovative Medicine increased 7.8%, and MedTech rose 4.5%. Adjusted earnings grew 4.7% to $2.90 per share.
Most of the growth was driven by Innovative Medicine. Declines in Stelara sales were balanced by gains in oncology drugs, as well as Tremfya, Spravato and Caplyta. J&J reported that Stelara’s decline cut operational growth for the segment by roughly 760 basis points.
OTTAVA stands out as the more straightforward MedTech choice. The system received De Novo authorization from the FDA on July 22, followed by an investor call scheduled for August 3. J&J notes its table-integrated system uses 30% to 50% less space compared to conventional systems. MedTech leader Tim Schmid stated that J&J is “pioneering a new category of surgical robotics with OTTAVA.” Johnson & Johnson Investor Relations
Investing in the pipeline continues to carry high costs. Depending on the achievement of certain milestones and exercise of options, Firefly and Sail may further cut 2027 adjusted earnings by an additional $1.36 per share. These agreements do not affect J&J’s yearly sales outlook.
Markets will be guided by macroeconomic events next week. U.S. consumer inflation figures are due on Wednesday, followed by producer price data on Thursday and retail sales results on Friday. J&J’s participation in the Wells Fargo conference is scheduled for September 9. According to FactSet, third-quarter earnings are set for October 20.
Risks: Stelara biosimilar erosion continues to pose significant risk. Commercial uptake for OTTAVA has yet to be established. Pipeline collaborations face execution challenges, and the suggested talc settlement remains legally uncertain.
This leaves the short-term outlook limited. Given just a 7.2% gap to the consensus target, additional upside depends on raised forecasts or proof that recent product launches can offset the earnings adjustment.
Related articles: NYSE:JNJ
